# C_2016455EN.01000601.xml

| 6.12.2016 | EN | Official Journal of the European Union | C 455/6 |
| --- | --- | --- | --- |

6.12.2016

EN

Official Journal of the European Union

C 455/6

---

Prior notification of a concentration

(Case M.7982 — Abbott Laboratories/Alere)

(Text with EEA relevance)

(2016/C 455/06)

| 1. | On 29 November 2016, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Abbott Laboratories (‘Abbott’, United States) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the undertaking Alere Inc. (‘Alere’, United States) by way of purchase of shares. |
| --- | --- |

1.

On 29 November 2016, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Abbott Laboratories (‘Abbott’, United States) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the undertaking Alere Inc. (‘Alere’, United States) by way of purchase of shares.

1

| 2. | The business activities of the undertakings concerned are:
  —   for Abbott: research, development, manufacture and sale of a broad line of health care products in established pharmaceutical, diagnostics, nutritional and vascular products, active globally,
  —   for Alere: production and sale of professional diagnostic solutions, mainly for infectious diseases, cardiometabolic diseases and toxicology, active globally. |
| --- | --- |

2.

The business activities of the undertakings concerned are:

—   for Abbott: research, development, manufacture and sale of a broad line of health care products in established pharmaceutical, diagnostics, nutritional and vascular products, active globally,

for Abbott

—   for Alere: production and sale of professional diagnostic solutions, mainly for infectious diseases, cardiometabolic diseases and toxicology, active globally.

for Alere

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.7982 — Abbott Laboratories/Alere, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.7982 — Abbott Laboratories/Alere, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---